84 related articles for article (PubMed ID: 20201734)
1. Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future.
Showalter SL; Charles S; Belin J; Cozzitorto J; Einstein P; Richards NG; Sauter PK; Kennedy EP; Witkiewicz A; Brody JR; Yeo CJ
Expert Opin Drug Deliv; 2010 Mar; 7(3):273-84. PubMed ID: 20201734
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs in the treatment of pancreatic cancer.
Mahalingam D; Kelly KR; Swords RT; Carew J; Nawrocki ST; Giles FJ
Expert Opin Emerg Drugs; 2009 Jun; 14(2):311-28. PubMed ID: 19466902
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Targeted agents in the treatment of pancreatic cancer: history and lessons learned.
Bendell J; Goldberg RM
Curr Opin Oncol; 2007 Jul; 19(4):390-5. PubMed ID: 17545806
[TBL] [Abstract][Full Text] [Related]
6. Controversies in the adjuvant treatment of pancreatic adenocarcinoma.
Saif MW
JOP; 2007 Sep; 8(5):545-52. PubMed ID: 17873458
[TBL] [Abstract][Full Text] [Related]
7. Novel targets for pancreatic cancer therapy.
Philip PA
Surg Oncol Clin N Am; 2010 Apr; 19(2):419-29. PubMed ID: 20159523
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress.
Wolff RA; Varadhachary GR; Evans DB
Ann Surg Oncol; 2008 Oct; 15(10):2773-86. PubMed ID: 18612703
[TBL] [Abstract][Full Text] [Related]
9. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
10. p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer.
Dong M; Nio Y; Yamasawa K; Toga T; Yue L; Harada T
J Surg Oncol; 2003 Feb; 82(2):111-20. PubMed ID: 12561067
[TBL] [Abstract][Full Text] [Related]
11. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
Burris HA; Rivkin S; Reynolds R; Harris J; Wax A; Gerstein H; Mettinger KL; Staddon A
Oncologist; 2005 Mar; 10(3):183-90. PubMed ID: 15793221
[TBL] [Abstract][Full Text] [Related]
13. The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure.
Ducreux M; Boige V; Goéré D; Deutsch E; Ezra P; Elias D; Malka D
Best Pract Res Clin Gastroenterol; 2007; 21(6):997-1014. PubMed ID: 18070700
[TBL] [Abstract][Full Text] [Related]
14. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
15. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
Chalasani P; Kurtin S; Dragovich T
JOP; 2008 May; 9(3):305-8. PubMed ID: 18469443
[TBL] [Abstract][Full Text] [Related]
16. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.
Günzburg WH; Salmons B
Acta Biochim Pol; 2005; 52(3):601-7. PubMed ID: 16175235
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
Murphy KM; Brune KA; Griffin C; Sollenberger JE; Petersen GM; Bansal R; Hruban RH; Kern SE
Cancer Res; 2002 Jul; 62(13):3789-93. PubMed ID: 12097290
[TBL] [Abstract][Full Text] [Related]
19. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients.
DeMichele A; Putt M; Zhang Y; Glick JH; Norman S
Cancer; 2003 May; 97(9):2150-9. PubMed ID: 12712466
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
Cohenuram M; Saif MW
JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
